News Ascendis Pharma A/S

Equities

ASND

US04351P1012

Real-time Estimate Cboe BZX Other stock markets 02:44:27 2024-04-19 pm EDT			5-day change	1st Jan Change
138.9 ^USD	-1.44%		-4.55%	+10.67%

05:11pm	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	MT
Apr. 18	European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	11:11am	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18	MT
Ascendis Pharma A/S : Form 6-K	Apr. 10	PU
JPMorgan Adjusts Ascendis Pharma A/S Price Target to $167 From $165, Maintains Overweight Rating	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday	Mar. 28	MT
Ascendis Pharma A/S : Form 6-K	Mar. 27	PU
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
Wells Fargo Raises Ascendis Pharma Price Target to $260 From $196, Maintains Overweight Rating	Mar. 15	MT
Ascendis Pharma A/S : Form 6-K	Mar. 14	PU
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	Mar. 13	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	Mar. 12	MT
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024	Mar. 04	AQ
Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer	Feb. 29	CI
European Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday Trading	Feb. 16	MT
European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading	Feb. 09	MT
Citigroup Raises Price Target on Ascendis Pharma to $182 From $146, Maintains Buy Rating	Feb. 08	MT
Wedbush Raises Ascendis Pharma's Pt to $225 From $207, Notes Multiple Catalysts Across Pipeline in Q4 2024; Keeps Outperform Rating	Feb. 08	MT
Ascendis Pharma Q4 Net Loss Narrows, Revenue Rises	Feb. 07	MT
Transcript : Ascendis Pharma A/S, 2023 Earnings Call, Feb 07, 2024	Feb. 07
Earnings Flash (ASND) ASCENDIS PHARMA Posts Q4 Revenue EUR137.7M	Feb. 07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Ascendis Pharma A/S

Equities

ASND

US04351P1012

Summary

Filters